| Identification | Back Directory | [Name]
Propanamide, 2-[3-[(3S)-3-[[[cyclopropyl[[4-(1H-pyrazol-4-yl)phenyl]methyl]amino]carbonyl]amino]-1-piperidinyl]phenoxy]-N-[2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]-2-methyl- | [CAS]
3003004-76-7 | [Synonyms]
Propanamide, 2-[3-[(3S)-3-[[[cyclopropyl[[4-(1H-pyrazol-4-yl)phenyl]methyl]amino]carbonyl]amino]-1-piperidinyl]phenoxy]-N-[2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]-2-methyl- | [Molecular Formula]
C35H45N7O5 | [MOL File]
3003004-76-7.mol | [Molecular Weight]
643.78 |
| Chemical Properties | Back Directory | [Boiling point ]
1004.5±65.0 °C(predicted) | [density ]
1.34±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
13.52±0.20(predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Antitumor agent-171 (Compound 35) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 1.61 μM. Antitumor agent-171 exhibits high affinity to β-catenin with Kd of 0.63 μM. Antitumor agent-171 inhibits the gene expression of axin2 with IC50 of 0.84 μM. Antitumor agent-171 inhibits cell viability of HCT116 with IC50 of 4.39 μM. Antitumor agent-171 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models[1]. | [References]
[1] Zhu W, et al., Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy through the Activation of Antigen Presentation of cDC1 Cells. J Med Chem. 2024 Jun 24. DOI:10.1021/acs.jmedchem.3c02079 |
|
|